Drilldown: Medicines
Medicines > classes 
:
Anti-amyloid beta (Aβ) monoclonal antibody or
Antiparkinsonian or
Benzodiazepine
:
Anti-amyloid beta (Aβ) monoclonal antibody or
Antiparkinsonian or
Benzodiazepine Use the filters below to narrow your results.
generic:
brand:
None (10) ·
Aduhelm (1) ·
Akineton (1) ·
Apokyn (1) ·
Artane (1) ·
Azilect (1) ·
Cogentin (1) ·
Comtan (1) ·
Dalmane (1) ·
Doral (1) ·
Dostinex (1) ·
Eldepryl (1) ·
Halcion (1) ·
Kisunla (1) ·
Leqembi (1) ·
Lexotan (1) ·
Librium (1) ·
Mogadon (1) ·
Neupro (1) ·
Onfi (1) ·
Ongentys (1) ·
Parlodel (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Serax (1) ·
Sinemet (1) ·
Symmetrel (1) ·
Tasmar (1) ·
Tranxene (1) ·
Versed (1) ·
Xadago (1) ·
Xanax (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Selective M1 muscarinic antagonist (1)
uses:
None (38) ·
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) ·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) ·
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
preparations:
None (38) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) ·
350 mg/20 mL vial for IV infusion (1) ·
Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 42 results in range #1 to #42.